The Relations Among Endotoxin, Inflammatory Cytokines, Cognitive Markers and Brain MRI Changes in Subjects With Depressive Disorder

Launched by LITHUANIAN UNIVERSITY OF HEALTH SCIENCES · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain substances in the body, called endotoxins and inflammatory cytokines, may affect the brain and contribute to symptoms of major depressive disorder (MDD). Researchers believe that inflammation could play a significant role in depression, but they want to learn more about how these substances interact and influence brain health. Specifically, they will look at whether low levels of endotoxins in the blood can lead to ongoing inflammation in the brain, which might worsen depressive symptoms and impact thinking abilities. The study also aims to explore the genetic factors that might affect how individuals respond to these changes.

To participate in this trial, individuals must be at least 18 years old and have a diagnosis of major depressive disorder. They should not have any other mental health disorders or serious physical illnesses that could affect inflammation levels. Participants will undergo tests to measure endotoxins and inflammatory markers in their blood, and they will also have brain scans to observe any related changes. This research is important because it may help identify new ways to understand and treat depression, especially for those who have not responded well to existing treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years old
• • signed informed consent
• • patients diagnosed with MDD (according to the WHO's \[2019\] International Classification of Diseases and related health problems categorization of mental disorders) for MDD group.
• Exclusion Criteria:
• • diagnosis of other mental disorders during the past one-year period (for MDD group).
• • diagnosis of any mental disorders within the past one-year period, previous suicide attempt, or current suicide risk identified in the study (for control group).
• • diagnosis of somatic diseases that may affect changes in inflammatory factors in the body (for both groups)